ISPC

iSpecimen is a pre-viability biospecimen-marketplace microcap where every lens points the same way: away. FY2025 revenue cratered to $1.93M from $9.29M — a 79.2% collapse — while the company still burned to a $10.5M net loss and a -465% operating margin. This is not a growth company hitting a speed bump; it is a business whose top line evaporated. Against that, the stock carries a $78.3M market cap and a P/S of 40.6x. Paying 40x sales for a company whose sales are shrinking four-fifths in a year is a valuation with no defensible support.

The filing removes any ambiguity. Management's own auditors attached a going-concern explanatory paragraph: 'These conditions raise substantial doubts about our ability to continue as a going concern,' with the plan explicitly dependent on 'obtaining additional financing, including public and private placements of capital stock' — for which there is 'no assurance' of success 'on acceptable terms, or if at all.' The company also disclosed a material weakness in internal control over financial reporting for FY2025, so even the reported numbers carry reliability risk. Accumulated deficit stands at $82.4M against just $3.09M of stockholders' equity.